Reported the week of August 14, 2026, a survey of nearly 5,600 women conducted by Balance@Work found that 79% of respondents had experienced hormone-related disruptions to their careers — including performance drops and increased absences — reframing hormone health from a private medical issue into a measurable workplace and economic one.

Why It Matters

This is the data femtech has been building toward — quantifying hormone health as a workforce-economics issue rather than a wellness nicety. That framing unlocks a B2B buyer (employers, benefits platforms, insurers) beyond the direct-to-consumer app market, and dovetails with a busy 2026 for menopause and hormone startups: continuous-hormone-monitoring wearables (Clair Health, Kahu SiliconBio), menopause telehealth (Hers, Midi, Evernow), and non-hormonal drug pipelines. The persistent access gap — two-thirds struggling to get HRT despite wanting it, against a backdrop of ongoing estrogen-patch shortages — is precisely the friction femtech and telehealth companies are positioning to monetize. It also strengthens the retention-and-accommodation business case that menopause-benefits vendors have been pitching to HR departments.

The numbers are pointed. With hormone imbalances driving brain fog, fatigue, and mood shifts, 76% of women said they felt held back by their symptoms, and roughly a quarter reported changing roles, passing up promotions, or leaving their company altogether. Taboo compounds the toll: most respondents had never received any hormone-health training, over half were unaware their workplace offered relevant accommodations, and a quarter were afraid to raise the topic with their manager. Notably, the survey pushes back on the reflex to file all of this under "menopause," reframing hormone health as a lifelong arc spanning PMS, PCOS, PMDD, endometriosis, and fertility.

Treatment access is the choke point. Hormone replacement therapy — which 70% of respondents were taking — proved effective at keeping women in work: nearly all said HRT improved their symptoms, and 19% said it directly helped them stay employed. Yet while 85% wanted to discuss hormone health with a provider, about two-thirds struggled to actually access HRT, with many searching for years and absorbing career disruption along the way. Separate coverage from UK outlets framed the takeaway bluntly: over a quarter of women have considered leaving the workforce because of hormone-related symptoms, and investing in workplace hormone-health initiatives could improve retention and productivity.

Sources

Update — 2026-08-16

Initial entry — story first created.